Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795479 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL1791098 | 0.98 | ALDH1A1 (0.45) | ALDH1A1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL30795926 | 0.98 | ALDH1A1 (0.45) | ALDH1A1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL30795801 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL1786371 | 0.88 | ALDH1A1 (0.50) | ALDH1A1KMT2ANPC1RAB9AEPHX2 | |
| SCHEMBL1791096 | 0.81 | HPGD (0.41) | ALDH1A1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL1791097 | 0.81 | HPGD (0.41) | ALDH1A1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL1789193 | 0.81 | MEN1 (0.45) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL30814174 | 0.81 | MEN1 (0.45) | ALDH1A1KMT2AKDM4EMEN1LMNA | |
| SCHEMBL1789475 | 0.80 | POLB (0.46) | ALDH1A1KMT2ANPC1RAB9AKCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | claimed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | claimed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | claimed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8629143-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2504317-A1 | POTASSIUM CHANNEL MODULATORS | Abbott Laboratories (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066168-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124642-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1644/4885KMT2A 474/4885NPC1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.